221
Views
22
CrossRef citations to date
0
Altmetric
Editorial

Current appraisal of single inhaler triple therapy in COPD

, &
Pages 3003-3009 | Published online: 28 Sep 2018

Figures & data

Figure 1 Schematic to show effects of inhaled corticosteroid (ICS) moiety of single triple inhaler therapy in COPD.

Notes: (A, B) The benefit is shown as attenuation of bronchial mucosal eosinophilic inflammation resulting in reduced exacerbations; (B, C) risk depicted as impaired mucociliary function with mucus retention and altered microbiome following initial viral infection, along with prolonged bronchial/alveolar ICS retention and resulting local immunosuppression, in turn producing consolidation (pneumonia).
Figure 1 Schematic to show effects of inhaled corticosteroid (ICS) moiety of single triple inhaler therapy in COPD.

Table 1 Key trials of single triple inhaler ICS/LABA/LAMA vs dual inhalers as either ICS/LABA or LABA/LAMA

Figure 2 Duration of lung retention with inhaled corticosteroids due to relative lipophilicity, which in turn determines pneumonia risk in COPD.

Note: Fluticasone furoate (FF), fluticasone propionate (FP), budesonide (BUD), and beclometasone dipropionate (BDP: via its active metabolite 17-BMP) – schematically depicted to reflect their respective kinetic terminal elimination half lives (FF.FP.BUD/BDP).
Abbreviation: 17-BMP, 17-beclometasone monopropionate.
Figure 2 Duration of lung retention with inhaled corticosteroids due to relative lipophilicity, which in turn determines pneumonia risk in COPD.